GB1356763A - Substituted benzimidazole derivatives - Google Patents

Substituted benzimidazole derivatives

Info

Publication number
GB1356763A
GB1356763A GB1791772A GB1791772A GB1356763A GB 1356763 A GB1356763 A GB 1356763A GB 1791772 A GB1791772 A GB 1791772A GB 1791772 A GB1791772 A GB 1791772A GB 1356763 A GB1356763 A GB 1356763A
Authority
GB
United Kingdom
Prior art keywords
prepared
methoxy
substituted
benzothiazolyl
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1791772A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of GB1356763A publication Critical patent/GB1356763A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1356763 2 - Benzo(heterocyclic)ethyl benzimidazoles and derivatives thereof MERCK & CO Inc 18 April 1972 [21 April 1971] 17917/72 Heading C2C [Also in Division C4] Novel compounds of the Formula I wherein m is 0, 1 or 2, n is 0 or 1, each R is C 1-5 alkyl, alkoxy, haloalkoxy or alkylthio, C 3-6 cycloalkoxy, C 2-6 alkenyl, or halogen or when m is 2 the R groups together form a methylene dioxy group; R 1 is hydrogen or C 1-5 alkyl; each R 2 is hydrogen or hydroxyl; X is carbonyl; A is oxygen, sulphur, nitrogen, imino, methylene or methine; the dotted lines indicate that a double bond is located at one of the two positions available between A and N with a hydrogen atom attached to N if valency considerations require it; with the provisos that when n is 0, A is not hydrogen or imino, and that when n is 0 and A is oxygen or sulphur at least one m is not 0; and acid addition salts thereof are prepared (a) by reacting the compounds and wherein R, R<SP>1</SP>, R 2 and m are as defined above Z is a carboxylic acid group, an aldehyde or Schiff base derivative thereof, or a nitrile, carboxylic ester, carboximidic ester or carboxylic amide group, and Z 1 is a group of the type defined for Z or is a group of the Formula IV wherein R, X, A, m and n and the dotted lines are as defined above and when Z 1 is a group of the type defined for Z reacting the intermediate of the formula wherein A* is oxygen or sulphur, and then closing the ring; and (b) reacting the above compound of Formula IV when Z is cyano with or when Z is other than cyano with to produce Various [2R,3R] - 2,3 - dihydroxy - 3 - (6- substituted - 2 - benzothiazolyl) - propion - [2- amino-4(5)-methoxy]anilides may be prepared by acetylation of the sodium salt of [2R,3R]-2, 3 - dihydroxy - 3 - (6 - substituted - 2 - benzothiazolyl propionic acid to yield the sodium salt of [2R,3R] - 2,3 - diacetoxy - 3 - (6 - substituted- 2-benzothiazolyl propionic acid which on treatment with 4-methoxy-o-phenylene diamine in the presence of acid and a dehydrating agent yields [2R,3R] - 2,3 - diacetoxy - 3 - (6 - substituted - 2 - benzothiazolyl) - propion - [2 - amino- 4(5)-methoxy]-anilide which on treatment with sodium methoxide yields the required compound. The sodium salt of [2R,3R]-2,3-dihydroxy-3- (6 - methoxy - 2 - benzothiazolyl)propionic acid may be prepared by reacting 2-amino-5-methoxythiophenol with L-diacetyl tartaric anhydride to yield [2R,3R]-2,3-diacetoxy-3-(6-methoxy-2-benzothiazolyl) propionic acid which was converted to its ammonium salt and hydrolsyed with sodium methoxide to the required compound. Various substituted 2-(#-cyanoethyl)benzimidazoles may be prepared by reacting the appropriate o-phenylenediamine with methyl-3-cyanopropyl carboximidate hydrochloride. Various ethyl - 3 - benzimidazolyl - (2) - propionimidate dihydrochlorides substituted in the benzimidazole ring may be prepared by reacting the appropriate 2-(#-cyanoethyl)benzimidazole with ethanol and hydrogen chloride in anhydrous conditions. [2R,3R] - 2,3 - Dihydroxy - 3 - [2 - 4(3H)- quinazolinonyl] - propion - [2 - amino - 4(5). methoxy]-anilide and various derivatives substituted in the 7-position of the quinazoline ring may be prepared by reaction of 4-methoxy-ophenylene diamine with the appropriate [2R, 3R] - 2,3 - dihydroxy - 3 - [2 - 4(3H) - quinazolinonyl]propionic acid which in turn is prepared by treatment of a [αR,#R]-diacetyltartar-2-carbamoyl anilide with sodium hydroxide, which anilide is prepared by treatment of an anthranilamide with L-diacetyl tartaric anhydride. Pharmaceutical compositions of the compounds I show antiviral activity when administered orally, parenterally, topically or as an oral or nasal spray with the usual excipients.
GB1791772A 1971-04-21 1972-04-18 Substituted benzimidazole derivatives Expired GB1356763A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13618671A 1971-04-21 1971-04-21
US13818671A 1971-04-21 1971-04-21

Publications (1)

Publication Number Publication Date
GB1356763A true GB1356763A (en) 1974-06-12

Family

ID=26834087

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1791772A Expired GB1356763A (en) 1971-04-21 1972-04-18 Substituted benzimidazole derivatives

Country Status (4)

Country Link
DE (1) DE2219408A1 (en)
FR (1) FR2133979B1 (en)
GB (1) GB1356763A (en)
NL (1) NL7204972A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035075A1 (en) * 2001-10-19 2003-05-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
US8546409B2 (en) 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
EP2663565A2 (en) * 2011-01-11 2013-11-20 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US8865730B2 (en) 2012-03-05 2014-10-21 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US9238070B2 (en) 2008-11-13 2016-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US9567337B2 (en) 2013-12-20 2017-02-14 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US9834564B2 (en) 2010-05-26 2017-12-05 Sunovion Pharmaceuticals Inc. Substituted quinolines as PDE-10 inhibitors
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111944340B (en) * 2020-08-21 2022-08-05 无锡市乐卡新材料有限公司 Salt-fog-resistant antirust coating

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623881B2 (en) 2000-04-25 2014-01-07 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6949535B2 (en) 2000-04-25 2005-09-27 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US8138195B2 (en) 2000-04-25 2012-03-20 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US9487772B2 (en) 2000-04-25 2016-11-08 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US10010550B2 (en) 2000-04-25 2018-07-03 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US8492389B2 (en) 2000-04-25 2013-07-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US10695349B2 (en) 2000-04-25 2020-06-30 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US8653077B2 (en) 2000-04-25 2014-02-18 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US8637533B2 (en) 2000-04-25 2014-01-28 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US10398695B2 (en) 2000-04-25 2019-09-03 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2003035075A1 (en) * 2001-10-19 2003-05-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US8207153B2 (en) 2004-05-13 2012-06-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
USRE44638E1 (en) 2004-05-13 2013-12-10 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US8586597B2 (en) 2004-05-13 2013-11-19 Icos Corporation 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
USRE44599E1 (en) 2004-05-13 2013-11-12 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US10336756B2 (en) 2004-05-13 2019-07-02 Icos Corporation (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta
US10906907B2 (en) 2004-05-13 2021-02-02 Icos Corporation Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof
US9149477B2 (en) 2004-05-13 2015-10-06 Icos Corporation 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
US8779131B2 (en) 2004-05-13 2014-07-15 Icos Corporation 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US8980901B2 (en) 2004-05-13 2015-03-17 Icos Corporation 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
US8993583B2 (en) 2004-05-13 2015-03-31 Icos Corporation 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
US9238070B2 (en) 2008-11-13 2016-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
US10154998B2 (en) 2008-11-13 2018-12-18 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
US8546409B2 (en) 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US10562916B2 (en) 2010-05-26 2020-02-18 Sunovion Pharmaceuticals, Inc. Substituted quinoxalines as PDE-10 inhibitors
US9834564B2 (en) 2010-05-26 2017-12-05 Sunovion Pharmaceuticals Inc. Substituted quinolines as PDE-10 inhibitors
EP3210984A1 (en) * 2011-01-11 2017-08-30 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN103619841B (en) * 2011-01-11 2017-03-29 桑诺维恩药品公司 Heteroaryl compound and its using method
US9856274B2 (en) 2011-01-11 2018-01-02 Sunovion Pharmaceuticals Inc. Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors
AU2012205687B2 (en) * 2011-01-11 2017-03-16 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
EP2663565A4 (en) * 2011-01-11 2014-07-02 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
AU2017204007B2 (en) * 2011-01-11 2018-11-08 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN103619841A (en) * 2011-01-11 2014-03-05 桑诺维恩药品公司 Heteroaryl compounds and methods of use thereof
EP2663565A2 (en) * 2011-01-11 2013-11-20 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US10570156B2 (en) 2011-01-11 2020-02-25 Sunovion Pharmaceuticals Inc. Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors
US10730879B2 (en) 2012-03-05 2020-08-04 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US8865730B2 (en) 2012-03-05 2014-10-21 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US9469643B2 (en) 2012-03-05 2016-10-18 Gilead Calistoga, LLC. Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US10047060B2 (en) 2013-12-20 2018-08-14 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US10442805B2 (en) 2013-12-20 2019-10-15 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US10414737B2 (en) 2013-12-20 2019-09-17 Gilead Sciences, Inc. Process methods for phosphatidylinositol 3-kinase inhibitors
US10059677B2 (en) 2013-12-20 2018-08-28 Gilead Calistoga Llc Process for preparing phosphatidylinositol 3-kinase inhibitors and intermediates thereof
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US9567337B2 (en) 2013-12-20 2017-02-14 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US10954199B2 (en) 2013-12-20 2021-03-23 Gilead Sciences, Inc. Process methods for phosphatidylinositol 3-kinase inhibitors
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
FR2133979B1 (en) 1975-10-31
DE2219408A1 (en) 1972-10-26
NL7204972A (en) 1972-10-24
FR2133979A1 (en) 1972-12-01

Similar Documents

Publication Publication Date Title
GB1356763A (en) Substituted benzimidazole derivatives
CA2612176C (en) Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors
GB1309835A (en) Trialkoxy-quinazolines
OA10661A (en) Benzimidazole compounds
TR200200648T2 (en) New dicarboxylic acid derivatives with pharmaceutical properties.
GB1180749A (en) A New Polycyclic Amine and Processes for its Production
US11780841B2 (en) 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same
GB1436893A (en) Tetrahydrocarbazole derivatives and process for their manufa cture
GB1328321A (en) 2-heteroaryl benzimidazole derivatives useful as anthelmintics
CN108727343A (en) Quinazolinones PARP-1/2 inhibitor containing 3- amino nafoxidines and preparation method thereof, pharmaceutical composition and purposes
US4423056A (en) 5(Aminomethyl)-4,5,6,7-tetrahydro[d]thiazole containing compositions for and medical use in treating circulatory insufficiencies
GB1530768A (en) 2-substituted-4-amino-6,7-dimethoxyquinazolines
GB1411583A (en) Aminophenyl-substituted alkyl-heterocyclic derivatives and processes for producing them
GB1301243A (en)
GB1259814A (en) Benzimidazoles
EA200001009A1 (en) PYRIDINE DERIVATIVES INHIBITING PHOSPHODYESTERASE IV
GB1515059A (en) 3-aminomethylene-6,7-dimethoxy-2-methyl-4-oxo-1,2,3,4-tetrahydro-1-quinoline carboxylic acid esters
ITMI942483A1 (en) PHARMACEUTICAL COMPOSITIONS WITH OSMOTIC CONTROLLED RELEASE AND DRUG DIFFUSION AND PROCEDURE FOR THEIR PREPARATION
US3920655A (en) Nitroimidazolyl benzoquinazolines
GB1490710A (en) Quinoxalinedione compounds as hypnotic agents
US3992374A (en) Amino-substituted nitroimidazolyl-methyleneaminoimidazolidinones
GB1174349A (en) Novel 2-Anilinomethylimidazoline Derivatives and process for the preparation thereof
Kim et al. Discovery of 2-(3, 5-difluoro-4-methylsulfonaminophenyl) propanamides as potent TRPV1 antagonists
GB1173212A (en) Hydantoins and processes for the preparation thereof
EP4104902A1 (en) Compound and drug containing same

Legal Events

Date Code Title Description
PS Patent sealed
PLNP Patent lapsed through nonpayment of renewal fees